Eldecalcitol.
Research-backed compound with potential health benefits. It's a potent, synthetic analog of active Vitamin D.
Reviewed March 2026
- Category
- Compound
What Eldecalcitol is, and what it does.
- Does it work
- For a healthy person looking for Vitamin D? Absolutely not. Stick with standard Vitamin D3.
- How much to take
- The standard clinical dose is 0.75 micrograms (mcg) per day. This is a decision for your doctor, not you.
- Time to feel it
- This is tracked on tests, not by sensation. Blood calcium responds within weeks, and bone density scans read out over six to twelve months.
- The first dose
- Nothing. You will not feel a thing. This is a long-term therapy with no immediate noticeable effect.
- With regular use
- Over 6-12 months, bone density scans should show improvement.
- How well tolerated
- Requires medical supervision. The main risk is hypercalcemia. Your doctor will need to monitor your blood calcium levels regularly.
- How it feels
- Like nothing. The benefits are invisible and are tracked with medical tests, not subjective feelings.
- The overlooked benefit
- It acts after the liver and kidney activation steps, so it does not raise the 25-hydroxyvitamin D figure a standard vitamin D status test reports.
0.5 to 0.8mcg a day is where Eldecalcitol works.
Source: Matsumoto et al., J Bone Miner Res, 2011
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Eldecalcitol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Bone mineral density at the spine and hipRandomised trial
- Intestinal calcium absorptionRandomised trial
- Bone turnover markersRandomised trial
- Muscle strength and balance in older adultsRandomised trial
- Longer circulating half-life than calcitriol through vitamin D binding protein affinityRandomised trial
Questions people ask about Eldecalcitol.
- Is this just a stronger Vitamin D?
- No. It's a synthetic drug designed to target bone density more specifically than regular D3. It's not a supplement.
- Can I buy this online without a prescription?
- You shouldn't. It requires medical monitoring. Buying from unverified sources is a massive risk to your health.
- What are the side effects?
- The big one is high blood calcium (hypercalcemia). This can cause nausea, confusion, and kidney problems. That's why blood tests are necessary.
- Does it help with mood or immunity like D3?
- It's designed and studied for bone and calcium metabolism. It is not used for the mood or immune support associated with standard Vitamin D.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
An active vitamin D receptor agonist raises the fraction of dietary calcium absorbed, which only helps if calcium is actually present in the gut. Co-administration is standard practice and was the design of a prospective observational study in postmenopausal women with reduced bone density. Raising both inputs at once also raises the need to monitor blood and urine calcium.
Carbonate is the usual calcium salt paired with an active vitamin D analogue and needs gastric acid to release the ionised calcium the analogue then helps absorb. Taken with food it dissolves more completely. The pairing supplies substrate to a transport step the analogue upregulates.
Eldecalcitol is an already-active analogue that binds the vitamin D receptor without needing hepatic and renal hydroxylation. Cholecalciferol sits upstream and raises the 25-hydroxyvitamin D pool that a status test measures. Taking both stacks receptor activation on top of substrate, so calcium status needs watching and the two are not interchangeable.
Vitamin D-driven signalling increases production of osteocalcin and matrix Gla protein, and both of those proteins require vitamin K-dependent gamma-carboxylation before they can bind calcium. Without adequate vitamin K, more of that protein circulates undercarboxylated. The relationship is one of a made protein and the enzyme cofactor that finishes it.
Magnesium is a cofactor for the hydroxylase enzymes of the vitamin D pathway and for parathyroid hormone signalling that governs calcium handling. Eldecalcitol bypasses the hydroxylation steps but the downstream calcium and parathyroid physiology still runs on magnesium. Magnesium status is therefore part of the picture even for an active analogue.
Vitamin D receptor activation raises intestinal absorption of phosphate as well as calcium, and bone mineral is laid down as calcium phosphate needing both. Serum phosphate is part of the standard monitoring alongside calcium. The two minerals move together under this signal.
The vitamin D receptor works as a heterodimer with the retinoid X receptor, whose ligand comes from vitamin A metabolism. High retinoid input can shift RXR partnering and change transcription driven by the vitamin D arm. The interaction is at the receptor level and is a reason to state retinol intake rather than a pairing to encourage.
Boron has been reported in small nutrition studies to influence calcium and magnesium retention and circulating vitamin D metabolites. The work is limited and the mechanism is not settled. It is an association-level note, not a demonstrated interaction with this analogue.
Nothing specific on file for Eldecalcitol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Eldecalcitol actually does.
Eldecalcitol is a synthetic analogue of 1,25-dihydroxyvitamin D3 carrying a 3-hydroxypropoxy substitution at the 2-beta position of the A ring.
Because it is already in the active configuration, eldecalcitol binds the vitamin D receptor directly and does not require hepatic 25-hydroxylation or renal 1-alpha-hydroxylation first.
The ligand-bound vitamin D receptor heterodimerises with the retinoid X receptor and drives transcription of the intestinal calcium transport machinery, including TRPV6 and calbindin-D9k, which raises the fraction of dietary calcium absorbed.
Because eldecalcitol acts downstream of the hydroxylation steps, taking it does not raise the 25-hydroxyvitamin D concentration that a standard vitamin D status test measures.
Where Eldecalcitol comes from.
It is built in a lab, step by step, by taking the active form of vitamin D and adding a small chemical arm to it. Nothing is harvested from a plant, an animal or the sun.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Manufacture begins from a steroid or secosteroid building block rather than from any biological vitamin D source. The starting materials are pharmaceutical fine chemicals.
The route builds the modified A ring carrying the 3-hydroxypropoxy group at the 2-beta position and couples it to the CD ring fragment, a convergent strategy typical of vitamin D analogue chemistry.
The product is purified to pharmaceutical grade, with related substances and stereoisomers controlled to specified limits, since the biological activity is stereochemistry-dependent.
Content is assayed and the impurity profile characterised against the registered specification. Potency is expressed in micrograms.
The purified compound is dissolved in an oil vehicle with an antioxidant and filled into light-protected soft capsules under controlled conditions.
The forms it comes in.
The essence, in one line each.
- Pooling clinical trials, eldecalcitol increased bone mineral density in older adults with low bone density, with raised blood and urine calcium as the main tolerability signal.Meta-analysis. Cui et al., 2022 (Archives of osteoporosis). PMID 35513519 ↗
- In Chinese adults with low bone density, eldecalcitol raised lumbar spine bone mineral density over the trial period without added vitamin D or calcium.Randomised trial. Jiang et al., 2019 (Journal of bone and mineral metabolism). PMID 31087185 ↗
- Across trials in older people, active vitamin D analogues including eldecalcitol were linked to better muscle strength measures and fewer falls than control.Meta-analysis. Xiong et al., 2024 (Frontiers in endocrinology). PMID 38362274 ↗
- Combining alendronate with eldecalcitol was compared against alendronate alone for bone mineral density and bone turnover markers in older adults with low bone density.Randomised trial. Sakai et al., 2015 (Osteoporosis international). PMID 25592133 ↗
- A comparative review of bone-protective interventions during aromatase inhibitor therapy, naming eldecalcitol among the compared options; the comparison is indirect across trials rather than head to head.Systematic review. Xu Y et al., 2025 (Frontiers in Oncology). PMID 41568387 ↗
- A randomised, blinded trial of active vitamin D in Japanese adults with impaired glucose regulation reporting progression to high blood sugar; the primary result did not reach the difference the trial was designed to detect, which is a failure to detect a difference rather than proof of none.Randomised trial. Kawahara T et al., 2022 (BMJ). PMID 35613725 ↗
- The design and rationale paper for that randomised, double-blind, placebo-controlled trial of active vitamin D, setting out the population, dose and endpoints in advance.Randomised trial. Kawahara T et al., 2016 (BMJ Open). PMID 27388357 ↗
- In a retrospective cohort of 314 adults with reduced bone density, prior therapy rather than vitamin D status was the factor associated with response to romosozumab; a retrospective association, not a causal finding.Cohort study. Nakano R et al., 2026 (Bone Reports). PMID 42088599 ↗
- A review of phase 4 trials of agents used for muscle loss and functional decline in older adults, naming eldecalcitol among the compounds surveyed.Narrative review. Alorfi NM et al., 2025 (Drug Design, Development and Therapy). PMID 40165996 ↗
These are the studies our verdict leans on, chosen from the 197 we read for Eldecalcitol. The full linked list is below.
The studies, linked.
9 sources behind our Eldecalcitol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEfficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)ClinicalTrials.gov ↗PHASE4 · 100 participants · Completed
- Clinical trialPharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsule 0.75 ug in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Single-center, Single-dose, Open-label, Two-period Crossover StudyClinicalTrials.gov ↗PHASE1 · 58 participants · Completed
- Clinical trialEDIROL Drug Intensive Monitoring: Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal OsteoporosisClinicalTrials.gov ↗1,000 participants · Unknown
- Clinical trialClinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia：a RCT TrialClinicalTrials.gov ↗PHASE4 · 450 participants · Recruiting
- Clinical trialEldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus AlfacalcidolClinicalTrials.gov ↗NA · 400 participants · Unknown
- Clinical trialStudy on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 DiabetesClinicalTrials.gov ↗NA · 358 participants · Not yet recruiting
- Clinical trialEfficacy and Safety of Eldecalcitol in Preventing Glucocorticoid-induced Bone Loss in Rheumatoid Arthritis Patients (ELEGANT)ClinicalTrials.gov ↗PHASE4 · 314 participants · Unknown
- Clinical trialComparison of the Efficacy and Safety With Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild OsteoporosisClinicalTrials.gov ↗PHASE4 · 300 participants · Unknown
- Clinical trialThe Effectiveness of Eldecalcitol in the Osteoporotic Patients Who Are Bisphosphonate Non-responders After Long-term Bisphosphonate TreatmentClinicalTrials.gov ↗PHASE1 · 100 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 2,919 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Eldecalcitol is, not how risky it is. A report is not proof Eldecalcitol caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.